Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12050017 | 0.85 | CNR2 (0.52) | CNR2EPHX2GPR119CHRM4CCR5 | |
| SCHEMBL9963213 | 0.84 | CNR2 (0.49) | CNR2EPHX2GPR119CHRM4CCR5 | |
| SCHEMBL15025228 | 0.84 | CNR2 (0.51) | CNR2EPHX2GPR119CHRM4CCR5 | |
| SCHEMBL12026465 | 0.84 | CNR2 (0.51) | CNR2EPHX2GPR119CHRM4CCR5 | |
| SCHEMBL19454523 | 0.81 | CNR2 (0.49) | CNR2EPHX2GPR119CHRM4CCR5 | |
| SCHEMBL19449797 | 0.81 | CNR2 (0.52) | CNR2EPHX2GPR119CHRM4CCR5 | |
| SCHEMBL10094568 | 0.81 | CNR2 (0.47) | CNR2EPHX2GPR119CHRM4CCR5 | |
| SCHEMBL6975824 | 0.81 | CNR2 (0.47) | CNR2EPHX2GPR119CHRM4CCR5 | |
| SCHEMBL10094552 | 0.80 | NPC1 (0.47) | CNR2EPHX2GPR119CHRM4CCR5 | |
| SCHEMBL15932036 | 0.79 | CNR2 (0.47) | CNR2EPHX2GPR119CHRM4CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291910-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| WO-2017175066-A1 | HETEROCYCLIC GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017175068-A1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291910-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | GPR119, GPR84, GPR65 | CNR2 71/4885EPHX2 934/4885GPR119 1/4885 |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | CNR2 57/4885EPHX2 921/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.